Antibody Development In-Vivo Reagent 
Drug Discovery World
OCTOBER 18, 2023
The research team, led by Professor Steve Watson and Dr Eleyna Martin, developed antibody fragments called nanobodies and crosslinked these to make ligands to four platelet receptors (GPVI, CLEC-2, FcɣRIIA and PEAR1). Reagents based on nanobodies will increase our understanding of platelet activation in the laboratory.
Drug Discovery World
APRIL 3, 2023
DS: What motivated you and Dr David Bunka, CTO, to create Aptamer and did you imagine you would one day be operating on such a global scale? I quickly recognised the commercial value of aptamers as being able to address the gap in the market where antibodies fail to perform, and together we established the business to begin aptamer development.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
OCTOBER 13, 2022
Over the two days at ExCel, 1554 delegates attended the event. Of those delegates, 75% work in drug discovery. There were 127 exhibitors, 180 posters, 40 technology speakers, 52 scientific speakers as well as a series of eight seminars focused on automation and technology which DDW organised and moderated in the dedicated Tech Theatre. .
Drug Discovery World
DECEMBER 13, 2023
In the ever-evolving landscape of therapeutic development, the role of antibodies has become increasingly apparent. Antibodies are used as therapeutics, components of therapeutics such as antibody-drug conjugates (ADC) and CAR-T cells, and as companion diagnostic tools. This article is sponsored by Fortis Life Sciences.
XTalks
APRIL 22, 2022
Both the areas of drug development and clinical trials are increasingly using in vitro assays to help determine the efficacy of an investigational therapeutic. All drug development processes evaluate a drug’s pharmacokinetics (PK) to gather data about its absorption, distribution, metabolism, and excretion in the body.
Drug Discovery World
NOVEMBER 30, 2023
Lightcast is developing a novel, programmable microfluidic platform that allows precise and highly flexible control of individual microdroplets using software-generated light patterns. The company’s goal is to accelerate functional characterisation and shortenoptimisation time in antibody discovery and t-cell workflows.
Drug Discovery World
FEBRUARY 15, 2023
Further discovery of PD-1 and CTLA4 as negative immune regulators led to the development of a new class of cancer therapeutics, namely the immune checkpoint inhibitors 5,6. Between 2017 and 2020, the number of IO therapies being developed has increased significantly from 2030 (for 265 targets) to 4,720 (for 504 targets).
Expert insights. Personalized for you.
52 
Let's personalize your content